Treat-And-Extend Versus Pro Re Nata Regimen of Intravitreal Conbercept Injection for Neovascular Age-Related Macular Degeneration: Results from COCOA, a Prospective, Open-Label, Multicenter, Randomized Phase IV Clinical Trial.

Purpose: To evaluate and contrast the effectiveness and safety of two conbercept treatment protocols-a three-dose treat-and-extend (3+T&E) regimen and a three-dose pro re nata (3+PRN) regimen-in Chinese patients diagnosed with neovascular age-related macular degeneration (nAMD).

Methods: Eligible patients, who had not undergone anti-VEGF intraocular injections within 3 months prior to enrollment, were randomly assigned to either the 3+T&E or 3+PRN regimen. The 3+T&E group received at least three monthly injections, with subsequent visit intervals extended based on disease activity assessment.

Insights into the compact CRISPR-Cas9d system.

Cas9d, the smallest known member of the Cas9 family, employs a compact domain architecture for effective target cleavage. However, the underlying mechanism remains unclear. Here, we present the cryo-EM structures of the Cas9d-sgRNA complex in both target-free and target-bound states.

Jugular Vein Evans Blue Injection for Blood-Brain Barrier Assessment Following Hemorrhagic Stroke in a Mouse Model.

The blood-brain barrier (BBB) is a selectively permeable membrane that plays a crucial role in protecting the brain from harmful substances. Its disruption is associated with various central nervous system (CNS) disorders, including hemorrhagic stroke. Evans Blue (EB) dye, a protein-binding tracer, is commonly used to assess BBB permeability.

Study on the multi-wavelength variation of 3C 454.3.

The variation mechanism of the blazar is still an open question. In this study, we collect the long-term multi-wavelength data of 3C 454.3 to conduct a comprehensive study.

Recanalization for Symptomatic Non-acute Intracranial Large Vessel Occlusion: An Observational Study.

Aim: This study investigated the efficacy and safety of endovascular revascularization for symptomatic non-acute atherosclerotic intracranial LVO.

Methods: For non-acute atherosclerotic intracranial large vessel occlusion (LVO), despite aggressive medical treatment, recurrent ischemic stroke or transient ischemic attack related to the occluded artery still occurs repeatedly. This retrospective cohort study included stroke patients with intracranial LVO who received endovascular treatment (EVT), categorized by successful recanalization and the time interval from symptom onset to revascularization (＜30 days vs.